Neupro

PreclinicalSmall molecule

UCB

Neupro is one of 60 small molecule programs targeting Parkinson disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson DiseaseUnknown

Restless Legs SyndromeUnknown

Parkinson DiseasePreclinical

Unknown

Restless Legs SyndromePreclinical

Unknown

Competition

Competitive Landscape

92 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Myrbetriq

Astellas

Approved

1 2

Medrol

Pfizer

Approved

1 3

Brintellix

Takeda

Approved

1 4

Dostinex

Golytely

Buspar

Cymbalta

Intropin

Neupro

Azilect

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parkinson's Disease1 trial

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

Completed· Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.·Phase 1·NCT02055274·39 enrolled

Restless Legs Syndrome1 trial

Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise

Completed· UCB logo

UCB··NCT01113710·687 enrolled

MPA1 trial

Adhesion and Safety of Rotigexole Compared to Neupro®

Not yet recruiting·EEva Pharma·N/A·NCT07015346·40 enrolled

Single Dose1 trial

An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Terminated· Novartis logo

Novartis·Phase 1·NCT04183634·31 enrolled

Treatment1 trial

Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support

Completed· UCB logo

UCB··NCT01330290·148 enrolled

1 more indication

Unspecified1 trial

The Practical Effect of Neupro

Unknown status·PPeking University Third Hospital··NCT04957420·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Neupro. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neupro compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neupro. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UCB company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UCB

Neupro

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parkinson's Disease1 trial

Restless Legs Syndrome1 trial

MPA1 trial

Single Dose1 trial

Treatment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News